CDR-Life — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

CDR-Life is a private, clinical-stage biotech leveraging its M-gager® T cell engager platform to create targeted therapies for solid tumors and autoimmune conditions. Founded by experienced drug developers, the company has generated six development candidates, with two already in clinical testing. Backed by a $76M Series A and strategic partnerships, CDR-Life is positioned to advance transformative treatments for hard-to-treat diseases.

OncologyAutoimmune Diseases

Technology Platform

M-gager® T cell engager (TCE) platform for developing highly selective bispecific antibodies that redirect T cells to kill target cells in cancer and autoimmune diseases.

Opportunities

The M-gager® platform's ability to target previously inaccessible antigens in solid tumors represents a major opportunity to address large unmet needs in oncology.

Additionally, applying TCE technology to selectively deplete pathogenic cells in autoimmune diseases could open a new frontier in precision immunology with blockbuster potential.

Risk Factors

Primary risks include clinical failure due to lack of efficacy or safety issues with its novel TCE constructs, particularly in solid tumors.

The company also faces intense competition from larger biopharma players in the bispecific antibody space and relies on future financing to sustain operations.

Competitive Landscape

CDR-Life competes in the crowded and rapidly evolving T cell engager/bispecific antibody arena against giants like Roche, Amgen, and Regeneron, as well as numerous biotechs. Its differentiation hinges on the claimed superior selectivity and targeting capabilities of the M-gager® platform for challenging solid tumor and autoimmune targets.

More companies in Biologics / Biosimilars →More companies in Switzerland →